RESMED INC quarterly report, Q3 FY2024

Full document

ResMed Inc. — Form 10-Q Summary

Reporting period: The filing covers the quarter and nine months ended March 31, 2024 (fiscal 2024 third quarter), filed April 25, 2024. This differs from the request metadata, which says “2023 Q3.” Financial figures below are in U.S. dollars; amounts are in millions unless stated otherwise.

Business context and results

ResMed designs and sells sleep and respiratory care products and provides software as a service (SaaS) to out-of-hospital care providers. Its two operating segments are Sleep and Respiratory Care and SaaS.

  • Quarter: Revenue was $1,197.0 million, up 7% year over year. Sleep and Respiratory Care revenue grew 7% to $1,049.0 million; SaaS revenue grew 8% to $148.0 million. Management attributed product growth primarily to increased demand and unit sales.
  • Nine months: Revenue was $3,462.1 million, up 12% reported and 11% on a constant-currency basis. Sleep and Respiratory Care grew 11%; SaaS grew 20%, or 9% excluding the MEDIFOX DAN acquisition.
  • Quarter profitability: Gross profit was $692.8 million, up 12%; gross margin was 57.9%, versus 55.3%. Operating income was $374.6 million, versus $300.7 million. Net income was $300.5 million, up 29%; diluted EPS was $2.04, versus $1.58.
  • Nine-month profitability: Gross profit was $1,939.8 million, up 12%, while gross margin was 56.0%, compared with 56.1%. Operating income was $938.7 million, versus $856.6 million; net income was $728.7 million, versus $667.9 million. Diluted EPS was $4.94, versus $4.53.
  • Cash flow: Nine-month operating cash flow was $961.1 million, versus $455.9 million. Management attributed the increase primarily to lower cash outflows for inventory purchases. Investing cash outflow was $223.3 million, versus $1,113.3 million, primarily reflecting the prior-year MEDIFOX DAN acquisition. Financing cash outflow was $726.0 million, versus $611.5 million of inflow, reflecting debt repayments, dividends and share repurchases.
  • Liquidity and debt: Cash and equivalents were $237.9 million. The company reported $1,175.0 million available on its revolving facility and $1,412.9 million of cash plus available revolving capacity. Balance-sheet debt, net of borrowing costs, was approximately $1,007.0 million, versus $1,441.1 million at June 30, 2023. The filing reports $1,010.0 million of gross debt outstanding and says the company was in compliance with debt covenants.
  • Other balance-sheet items: Total assets were $6,814.6 million and stockholders’ equity was $4,629.9 million at March 31, 2024. Inventory was $829.5 million, down from $998.0 million at June 30, 2023.

Material changes and notable items

  • Quarterly gross-margin improvement reflected lower freight costs and manufacturing cost improvements. Nine-month margin was slightly lower, with field safety notification costs and higher acquired-intangible amortization partly offset by SaaS mix and cost improvements.
  • Nine-month operating results included $64.2 million of restructuring charges: $28.6 million for severance and termination benefits, $33.2 million of intangible impairments and $2.4 million of other asset impairments. The restructuring was substantially complete by March 31; no restructuring expense was recorded in the quarter.
  • Nine-month field safety notification costs totaled $14.3 million: $6.4 million related to providing alternative masks following updated contraindications for masks with magnets, and $7.9 million related to component replacement in certain Astral ventilation devices manufactured from 2013 to 2019.
  • Quarterly net income included a $13.9 million gain on equity investments. Nine-month interest expense rose to $39.8 million from $32.4 million, which management attributed to higher debt associated with MEDIFOX DAN financing.
  • The company paid $211.8 million in dividends during the nine months and repurchased $100.0 million of shares. A $0.48-per-share dividend was declared after quarter-end, payable June 13, 2024, subject to the stated record date.

Outlook, risks and contingencies

ResMed provided no specific revenue or earnings guidance in the supplied filing text. Management said existing liquidity should fund operations and expected capital expenditures for the next 12 months and beyond, while noting that cash flow may vary with operating results, supply-chain conditions, working capital and capital deployment. Management highlighted ongoing investment in research and development, including AirSense 11 product features and digital health technologies, and described a new operating model intended to accelerate product development and profitable growth.

  • Risks discussed include foreign-exchange exposure, inflation and the possibility that higher product, freight, overhead or wage costs could pressure margins if not offset; variable-rate debt; and broader market, regulatory, supply-chain and macroeconomic uncertainties.
  • Patent litigation includes NYU’s appeal of patent invalidations, with resolution not expected before March 2025, and ongoing Cleveland Medical Devices litigation. The company said it could not reasonably estimate potential losses, if any, on open matters.
  • Customer receivables sold with limited recourse had a maximum outstanding exposure of $35.0 million and an associated provision of $0.8 million at March 31, 2024. The company reported no significant off-balance-sheet arrangements.
  • Management concluded disclosure controls were effective as of March 31, 2024 and reported no material change in internal control over financial reporting during the quarter.

Important facts for investors to verify

  • Confirm the intended period: the filing is for the quarter ended March 31, 2024, not 2023 Q3.
  • Track demand, unit sales and margins across devices, masks and SaaS, including SaaS growth excluding MEDIFOX DAN.
  • Assess whether operating cash flow remains strong after the inventory-related working-capital benefit and whether debt repayment continues.
  • Monitor costs and remaining exposure from the mask and Astral field safety notifications, restructuring actions and related impairments.
  • Review developments in NYU and Cleveland Medical Devices litigation and the company’s ability to maintain covenant compliance and manage foreign-exchange and interest-rate risks.